Literature DB >> 26975035

Clinicopathologic Spectrum of Gastrointestinal T-cell Lymphoma: Reappraisal Based on T-cell Receptor Immunophenotypes.

Tsutomu Tanaka1, Hideko Yamamoto, Ahmed Ali Elsayed, Akira Satou, Naoko Asano, Kei Kohno, Tomohiro Kinoshita, Yasumasa Niwa, Hidemi Goto, Shigeo Nakamura, Seiichi Kato.   

Abstract

The differential diagnosis of primary gastrointestinal EBV T-cell lymphoma (GITCL) includes enteropathy-associated T-cell lymphoma (EATL), peripheral T-cell lymphoma, not otherwise specified, adult T-cell leukemia/lymphoma, and anaplastic large cell lymphoma. Type II EATL is considered to be a tumor of intraepithelial lymphocytes. However, the evaluation of intraepithelial lymphocytosis by biopsy specimens is challenging, which poses a diagnostic problem between the EATL and peripheral T-cell lymphoma, not otherwise specified. This situation requested us to establish a pragmatic diagnostic approach for the classification of GITCL. We identified 42 cases of GITCL and analyzed clinicopathologic features, especially addressing their T-cell receptor (TCR) phenotype. Nine (21%) of 42 GITCL cases were positive for TCRγ protein expression. Among these TCRγ cases, TCRβ expression or not was detected in 5 and 4, respectively, but resulted in no further clinicopathologic differences. TCRβ positivity without TCRγ expression (βγ) was seen in 9 GITCL patients (21%). Twenty-four patients (57%) were negative for TCRβ and γ expression (βγ). Compared with TCRβγ or βγ type, TCRγ cases were characterized by exclusive involvement of intestinal sites (100% vs. 11%, P<0.001; 100% vs. 58%, P=0.032, respectively), but not of stomach (0% vs. 78%, P=0.002; 0% vs. 38%, P=0.039, respectively). Notably, TCRγ positivity was an independent unfavorable prognostic factor among our GITCL patients (P<0.001). Considering our results, TCRγ GITCL, that is, intestinal γδ T-cell lymphoma, appears to constitute a distinct disease entity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26975035     DOI: 10.1097/PAS.0000000000000630

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2016-06-13       Impact factor: 0.196

Review 2.  Intraepithelial lymphocytes, scores, mimickers and challenges in diagnosing gluten-sensitive enteropathy (celiac disease).

Authors:  Consolato Sergi; Fan Shen; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

3.  γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature γδ T-Cell Malignancies.

Authors:  Eric X Wei; Vasiliki Leventaki; John K Choi; Susana C Raimondi; Elizabeth M Azzato; Sheila A Shurtleff; Menchu G Ong; Diana M Veillon; James D Cotelingam; Rodney E Shackelford
Journal:  Case Rep Hematol       Date:  2017-09-24

Review 4.  Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification.

Authors:  Seiichi Kato; Daisuke Yamashita; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2020

5.  Reappraisal of nodal Epstein-Barr Virus-negative cytotoxic T-cell lymphoma: Identification of indolent CD5+ diseases.

Authors:  Daisuke Yamashita; Kazuyuki Shimada; Katsuyoshi Takata; Tomoko Miyata-Takata; Kei Kohno; Akira Satou; Ayako Sakakibara; Shigeo Nakamura; Naoko Asano; Seiichi Kato
Journal:  Cancer Sci       Date:  2018-06-26       Impact factor: 6.716

6.  PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.

Authors:  Daisuke Yamashita; Kazuyuki Shimada; Kei Kohno; Yasunori Kogure; Keisuke Kataoka; Taishi Takahara; Yuka Suzuki; Akira Satou; Ayako Sakakibara; Shigeo Nakamura; Naoko Asano; Seiichi Kato
Journal:  Pathol Int       Date:  2020-05-18       Impact factor: 2.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.